Product nameDMXAA (ASA404), VEGFR inhibitor
DescriptionVascular disrupting agent. VEGFR inhibitor.
Biological descriptionVascular disrupting agent. VEGFR inhibitor. Potent type I interferon inducer. Increases vascular permeability and vascular endothelial apoptosis. Inhibits angiogenesis. Shows antiviral and antitumor effects in vivo.
Chemical name2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic acid
Storage instructionsStore at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 25 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
- Receptors & Transporters
- Enzyme-Linked Receptors
- Receptor tyrosine kinases
All lanes : Anti-Interferon beta antibody [EPR22186-266] (ab218229) at 1/1000 dilution
Lane 1 : Untreated RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
Lane 2 : RAW 264.7 treated with 50 µg/ml DMXAA (ab143018) for 7 hours, then with 300 ng/ml Brefeldin A (BFA) added after 1 hour, whole cell lysate
Lane 3 : Untreated RAW 264.7 whole cell lysate
Lane 4 : RAW264.7 treated with 100 ng/ml lipopolysaccharide (LPS) for 6 hours, then with 300 ng/ml Brefeldin A (BFA) added after 3 hours, whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Observed band size: 24,26 kDa why is the actual band size different from the predicted?
Exposure time : Lanes 1 and 2: 26 seconds; Lanes 3 and 4: 3 minutes.
Blocking/Dilution buffer: 5% NFDM/TBST.
Interferon beta can be induced to increase the expression by DMXAA or LPS in RAW264.7 cell (PMID: 23027866, PMID: 16020513).
The doublet is likely due to isoforms (PMID: 7352261).
Interferon beta was immunoprecipitated from 0.35 mg of RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) treated with 50μg/ml DMXAA (ab143018) for 1h, then together with 300ng/ml brefeldin A (BFA) for another 6h whole cell lysate with ab218229 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab218229 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1: RAW 264.7 (treated with DMXAA (ab143018)/BFA) whole cell lysate 10 μg (Input).
Lane 2: ab218229 IP in RAW 264.7 (treated with DMXAA (ab143018)/BFA) whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab218229 in RAW 264.7 (treated with DMXAA (ab143018)/BFA) whole cell lysate.
Blocking and dilution buffer: 5% NFDM/TBST.
This product has been referenced in:
- Fridlender ZG et al. Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 108:1288-97 (2013). Read more (PubMed: 23481183) »
- Tijono SM et al. Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br J Cancer 108:1306-15 (2013). Read more (PubMed: 23481185) »
- Tang CK et al. The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant. PLoS One 8:e60038 (2013). Read more (PubMed: 23555875) »